跳至主要内容
临床试验/NCT02521506
NCT02521506已完成不适用

Clinical Efficacy of OneTouch® Verio™IQ Meter

Fundación Pública Andaluza Progreso y Salud8 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2015年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
90
试验地点
8
主要终点
number of hypoglycemic events

研究概览

简要总结

Diabetes mellitus is one of the most prevalent disease in the western world. The control of glucose levels has a big impact in the prevention of diabetes complications. The measure of glucose levels in capillary blood with glucometers is the gold standard to measure and control the glucose levels. Nowadays the glucometers become to more precise and sophisticated devices. One of the most notables advance is the inclusion of software that cam predicts glucose trends. This software has not be tested in routine clinical practice.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient diagnosed with diabetes mellitus 1 or 2
  • Treatment with insulin regimen during at least 12 months
  • Capability of performed 3 glucose measurement per day
  • Levels of glycated hemoglobin (A1C) less than 10%

排除标准

  • Patients diagnosed of mental disorders
  • Patients included in structured therapeutic health 6 months before the inclusion
  • Patients included in any clinical trial in the 4 months before the inclusion

结局指标

主要结局

number of hypoglycemic events

时间窗: 20 months

Glucose levels under 70 mg/dL with or without clinical manifestation

次要结局

未报告次要终点

研究者

发起方
Fundación Pública Andaluza Progreso y Salud
申办方类型
Other
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验